Consultant and Investment Group Company Psc

The company maintains a debt-to-equity ratio of 0.64, indicating a moderate reliance on debt financing. However, its liquidity position is constrained, with a current ratio of 1.06, suggesting limited capacity to meet short-term obligations. The negative operating cash flow of -906,980 JOD and free cash flow of -287,460 JOD highlight ongoing cash flow challenges, which could pressure liquidity further. The company's return on equity of 0.61% and return on assets of 0.32% are below typical thresholds for capital efficiency in the healthcare sector, indicating suboptimal asset and equity utilization.

Profitability metrics show a gross profit margin of 23.8% (1,173,970 JOD / 4,931,510 JOD revenue), which is in line with the industry median for healthcare facilities and services. However, the operating margin of 5.04% (248,970 JOD / 4,931,510 JOD revenue) and net margin of 2.74% (135,150 JOD / 4,931,510 JOD revenue) are below the sector average, suggesting higher operational costs or pricing pressures.

The company's revenue is concentrated in a single segment, pharmaceuticals, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks, such as regulatory changes or supply chain disruptions. The absence of segment or geographic breakdowns in the financial data limits the ability to assess risk distribution.

The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the most recent period. The capital expenditure of -788,820 JOD indicates a reduction in investment, which may signal a strategic shift or financial constraint. The outlook for the current fiscal year is neutral, with no significant directional change in revenue or profitability expected.

The risk assessment highlights liquidity as a medium concern, with the company's cash and equivalents of 363,910 JOD insufficient to cover its long-term debt of 14,127,510 JOD. The dilution risk is low, as the number of shares outstanding remains unchanged between basic and diluted shares. No recent events, such as filings or transcripts, have been disclosed to provide further insight into the company's strategic direction or risk profile.

Net income surged 34.4% year-over-year to JOD 1.87 million, demonstrating strong recent profitability growth.

Operating income expanded 37.3% year-over-year, indicating significant improvement in core operational efficiency and earnings power.

Revenue grew 8.7% year-over-year to JOD 24.4 million, reflecting consistent top-line expansion over the period.

Long-term debt decreased slightly to JOD 13.5 million, suggesting a modest reduction in leverage obligations.

Return on equity of 0.61% is significantly below the healthcare cohort median of 4.56%, indicating poor capital efficiency.

The company faces high credit risk, posing a significant threat to financial stability and potential losses.

Debt-to-equity ratio of 0.64 is double the cohort median of 0.32, indicating higher financial leverage risk.

Cash conversion of -6.71 is in the bottom quartile, signaling poor ability to generate cash from operations.